Rocket Pharmaceuticals
RCKT
186 hedge funds and large institutions have $323M invested in Rocket Pharmaceuticals in 2025 Q4 according to their latest regulatory filings, with 31 funds opening new positions, 60 increasing their positions, 71 reducing their positions, and 18 closing their positions.
72% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 18
70% more call options, than puts
Call options by funds: $325K | Put options by funds: $191K
8% more funds holding
Funds holding: 173 → 186 (+13)
3% more capital invested
Capital invested by funds: $315M → $323M (+$7.91M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
5.19% less ownership
Funds ownership: 89.52% → 84.33% (-5.2%)
15% less repeat investments, than reductions
Existing positions increased: 60 | Existing positions reduced: 71
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citigroup
New York
|
+$17.9M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$5.66M |
| 3 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$3.27M |
| 4 |
BlackRock
New York
|
+$2.71M |
| 5 |
Two Sigma Investments
New York
|
+$1.79M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MC
Maverick Capital
Dallas,
Texas
|
-$20.4M |
| 2 |
MB
MPM BioImpact
Boston,
Massachusetts
|
-$7.93M |
| 3 |
Millennium Management
New York
|
-$6.11M |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
-$3.13M |
| 5 |
SCM
Suvretta Capital Management
New York
|
-$2.91M |
RCKT Hedge Fund Activity: Q4 2025 in Review
186 of the 8,266 institutional investors tracked by Wall St. Rank reported a position in Rocket Pharmaceuticals (RCKT) for Q4 2025, worth a combined $323M — up 2.5% from $315M a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new RCKT positions and 18 closed out — a net gain of 13 holders — while 60 added to existing stakes and 71 trimmed.
The largest buyer was Citigroup, adding an estimated $17.9M. The largest seller was Maverick Capital, cutting an estimated $20.4M.
- 186 institutional investors held Rocket Pharmaceuticals (RCKT) as of Q4 2025, up from 173 in Q3 2025.
- Funds reported $323M of Rocket Pharmaceuticals stock for Q4 2025, up 2.5% quarter-over-quarter.
- 31 funds opened new Rocket Pharmaceuticals positions in Q4 2025 and 18 closed out, a net change of +13 holders.
- The largest Rocket Pharmaceuticals buyer in Q4 2025 was Citigroup, an estimated $17.9M added.
- The largest Rocket Pharmaceuticals seller in Q4 2025 was Maverick Capital, an estimated $20.4M sold.
Based on aggregated 13F filings for Q4 2025.